T. Rowe Price Associates
SPTX

T. Rowe Price Associates’s Seaport Therapeutics SPTX Stock Holding History

T. Rowe Price Associates’s Portfolio SPTX Stock Details SPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.4M Buy
+1,308,604
New +$23M ﹤0.01% 1054

Other funds holding SPTX

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates's SPTX Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Seaport Therapeutics (SPTX) in Q2 2026: 1,308,604 shares worth $28.4M. The stake represents ﹤0.01% of the portfolio and ranks #1054 among its holdings.

47 funds tracked by Wall St. Rank hold SPTX as of Q2 2026.

  • T. Rowe Price Associates held 1,308,604 shares of Seaport Therapeutics worth $28.4M as of Q2 2026.
  • Seaport Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Seaport Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1054 holding.
  • 47 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.